公开(公告)号：US20190142796A1

公开(公告)日：2019-05-16

申请号：US16190298

申请日：2018-11-14

Applicant: NOVARTIS AG

Inventor： Tinya ABRAMS ,  Larry Alexander GAITHER

IPC: A61K31/381 ,  A61K31/519 ,  A61P35/00 ,  A61K9/00

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US20190167652A1

公开(公告)日：2019-06-06

申请号：US16204471

申请日：2018-11-29

Applicant: NOVARTIS AG

Inventor： Tinya ABRAMS ,  Larry Alexander GAITHER

IPC: A61K31/4439 ,  A61K31/381 ,  A61P35/00

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and alpelisib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with PI3K inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US20220031657A1

公开(公告)日：2022-02-03

申请号：US17502986

申请日：2021-10-15

Applicant: NOVARTIS AG

Inventor： Tinya ABRAMS ,  Larry Alexander GAITHER

IPC: A61K31/381 ,  A61K9/00 ,  A61P35/00 ,  A61K31/519

Abstract: The present invention relates to a pharmaceutical combination comprising LSZ102 and ribociclib; pharmaceutical compositions comprising the same; and methods of using such combinations and compositions in the treatment or prevention of conditions in which degradation of estrogen receptors combined with CDK4/6 inhibition is beneficial in, for example, the treatment of cancers.

公开(公告)号：US20180193475A1

公开(公告)日：2018-07-12

申请号：US15329818

申请日：2015-07-27

Applicant: Novartis AG

Inventor： Tinya ABRAMS ,  Steven Bruce COHEN ,  Dylan DANIEL ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Thomas HUBER ,  William MALLET ,  Matthew John MEYER ,  Weijia OU ,  Siew Ho SCHLEYER ,  Kathrin Ulrike TISSOT-DAGUETTE

IPC: A61K47/68 ,  A61K39/395 ,  C07K16/28 ,  A61P35/02

CPC classification number: A61K47/6803 ,  A61K39/39558 ,  A61K47/6849 ,  A61K49/00 ,  A61K51/103 ,  A61K51/1093 ,  A61K2039/505 ,  A61K2039/545 ,  A61P35/02 ,  C07K16/2803 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/77 ,  C07K2317/92

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.

公开(公告)号：US20180125996A1

公开(公告)日：2018-05-10

申请号：US15690737

申请日：2017-08-30

Applicant: Novartis AG

Inventor： Tinya ABRAMS ,  Steven COHEN ,  Christie P. FANTON ,  Catrin FINNER ,  Thomas HUBER ,  Kathy MILLER ,  Siew Ho SCHLEYER ,  Kathrin Ulrike TISSOT-DAGUETTE

IPC: C07K16/28 ,  A61K9/00 ,  A61K9/19 ,  A61K31/537 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K39/00

CPC classification number: A61K47/6803 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/537 ,  A61K39/39591 ,  A61K45/06 ,  A61K47/12 ,  A61K47/26 ,  A61K47/6801 ,  A61K47/6849 ,  A61K47/6855 ,  A61K47/6857 ,  A61K47/6865 ,  A61K47/6867 ,  A61K47/6889 ,  A61K47/6921 ,  A61K49/00 ,  A61K51/103 ,  A61K51/1093 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/53 ,  G01N33/574 ,  G01N33/57492

Abstract: The present invention relates to anti-cKIT antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.